Type something and hit enter



Official Telegram : https://www.telegram.me/kimstock 
Official Website   : http://www.kimstockwatch.com/

DATE : 21 December 2020




ABOUT -  Duopharma Biotech Berhad
Duopharma Biotech Group (“Duopharma Biotech” or “the Company”) began with the establishment of Duopharma (M) Sendirian Berhad in 1979. Duopharma Biotech was incorporated in 2000 and is today one of Malaysia’s leading pharmaceutical companies listed on the Main Market of Bursa Malaysia Berhad.
Duopharma Biotech has core competencies in the pharmaceutical industry inclusive of Manufacturing, Research & Development and Commercialisation & Marketing of over 300 generic drugs such as Omesec and Prelica as well as Consumer Healthcare (“CHC”) products including CHAMPS®, FLAVETTES®, PROVITON® and Uphamol, which are well-recognised and accepted by consumers in Malaysia, regionally and globally. The Company has also diversified into the biosimilars space with technology and commercialisation collaborations with credible and strong international partners.
Headquartered in Kuala Lumpur, Malaysia, Duopharma Biotech owns and operates three manufacturing plants in Klang, Bangi and Glenmarie, Selangor. Duopharma Biotech also has subsidiary companies in the Philippines and Singapore. A subsidiary of Duopharma Biotech Berhad has a representative office in Jakarta, Indonesia.
KEY PERSON -  Duopharma Biotech Berhad
CHART -  Duopharma Biotech Berhad
DPHARMA - This is good fundamental stocks. Due to vaccines play theme, I would like to see this stock going to spike till February 2021. My prediction as per my target price below.
KIM'S TP -  Duopharma Biotech Berhad
TP1 : RM4.50 
TP2 : RM5.80
TP3 : RM7.00
Cheap Call Warrant :  "TO BE HOT CAKES"
FINANCIAL -  Duopharma Biotech Berhad




"If you thinking about who will be COVID-19 vaccine distributor in Malaysia? You must give priority and alert this 2 giants "PHARMANIAGA & DUOPHARMA" then only the others vaccine players" - Kim


- Positive developments in the development of a Covid-19 vaccine will continue to lift interest in local pharmaceutical manufacturers, including PHARMANIAGA & DUOPHARMA, which is touted to be among the frontrunners to win a tender for the vaccine.

- Pharmaniaga has several advantages to clinch the fill and finish tender given its well-established logistics and distribution network nationwide.

- Additionally, the company has a large capacity of sterile and liquid plant to conduct the process for the vaccine. Pharmaniaga’s small volume injectable (SVI) plant in Puchong, Selangor has the capacity to produce 10 million doses per month.

- Assumptions took into account, among others, price inflation from potential surge in demand for vaccine containers, local currency exchange rate, scalability of Pharmaniaga versus international peers, expected margin from the tender and a 50%-50% tender split with DUOPHARMA Biotech.





1. Malaysia to get AstraZeneca Covid-19 vaccine, follows Pfizer-BioNTech deal

  • Malaysia said on 19 DEC it has secured coronavirus vaccine from AstraZeneca PLC, on the heels of news it will receive the Pfizer-BioNTech vaccine in February as it grapples with a surge in infections.
  • The AstraZeneca deal, to be signed on Monday 21 DEC, will allow immunisation of about 20 per cent of Malaysia’s population of 32 million, similar to that of the deal with US giant Pfizer Inc and its German partner BioNTech SE, said Health Minister Adham Baba.
  • Malaysia expects to receive enough vaccines to inoculate 10 per cent of the population through the global Covax facility, backed by the World Health Organisation, he said in a statement.
  • The government is working to secure more deals to expand inoculation to 70 per cent of the population, Datuk Seri Adham said.
  • The government expects to receive the first batch of Pfizer-BioNTech vaccine doses in February, national news wire Bernama said.
  • Last month, Malaysia announced it had agreed to buy 12.8 million doses of the vaccine, becoming the first country in South-east Asia to strike a deal with the US drugmaker.
  • Under the deal, Pfizer will deliver the first one million doses in the first quarter of 2021, with 1.7 million, 5.8 million and 4.3 million doses to follow in subsequent quarters.
  • Pfizer and their German partners BioNTech have supply deals with several countries including the United States, Germany, Japan, Canada, Australia and Britain.


2. Duopharma to partner with OEM in Indonesia, Singapore 

  • Duopharma Biotech Bhd is in talks with original equipment manufacturers (OEM) in countries like Indonesia, Singapore and the Philippines to produce vitamin C supplements, in line with its plan to strengthen its consumer healthcare segment in Southeast Asia.
  • Chief executive officer Shamsul Idham Ahad said the demand for Flavettes Effervescent Vitamin C grew by 30% this year, and the supplement has emerged as a best seller in the market due to the rising public belief that it helps to boost the immune system amidst the Covid-19 pandemic.


3. Duopharma stock rises as EPF increases stake

  • Duopharma Biotech stock price has seen a steady rise since July amid vaccine optimism and it is expected to continue its upward momentum as the Employees Provident Fund (EPF) has increased its holdings.
  • The two top pharmaceutical companies in Malaysia, namely Pharmaniaga, which is owned by the Armed Forces Fund Board (LTAT), and Duopharma would be the biggest gainers once the COVID-19 vaccine is available.
  • In terms of stake, Duopharma’s majority shareholder Bumiputera Investment Foundation holds 46.5 per cent, EPF (7.82 per cent) and Permodalan Nasional Bhd (4.94 per cent).



  • With this 3 points added, You will see DPHARMA STOCK WILL RISE HIGHER.




Lastly, don't forget to click on our telegram link above and join us. Let us give you the latest update on the stock market and our group development. We hope you enjoy reading our blogs and give us your support.  

If you would like to know more about Kim's Group Trader (KGT) and Kim's Investment Club (KIC). You may reach out to us via link above. 
Best Regards,

Disclaimers: The research, information and financial opinions expressed in this article are purely for information and educational purpose only. We do not make any recommendation for the intention of trading purposes nor is it an advice to trade. Although best efforts are made to ensure that all information is accurate and up to date, occasionally errors and misprints may occur which are unintentional. It would help if you did not rely upon the material and information. We will not be liable for any false, inaccurate, incomplete information and losses or damages suffered from your action. It would be best if you did your own research to make your personal investment decisions wisely or consult your investment advisor.



Click to comment
Back to Top
Back to Top